Literature DB >> 16481223

Dysregulated interleukin-8 secretion and NF-kappaB activity in human cystic fibrosis nasal epithelial cells.

Salvatore Carrabino1, Daniela Carpani, Alessandra Livraghi, Maurizio Di Cicco, Diana Costantini, Elena Copreni, Carla Colombo, Massimo Conese.   

Abstract

BACKGROUND: It is not clear whether cystic fibrosis (CF) airway inflammation is a consequence of bacterial infection or is intrinsically dysregulated. The aim of this study was to investigate IL-8 secretion and NF-kappaB activity in primary respiratory epithelial cells cultured from nasal polyps obtained from CF and non-CF subjects.
METHODS: NF-kappaB activity was studied by electrophoretic mobility-shift and quantitative colorimetric assays in nuclear extracts. Immunoreactive IL-8 levels were assessed by ELISA in cell culture supernatants. Both parameters were studied at baseline and following challenge with Pseudomonas aeruginosa or stimulation with pro-inflammatory cytokines.
RESULTS: Under basal conditions, CF cells presented a significant higher activity of NF-kappaB than non-CF cells (P=0.0004). P. aeruginosa challenge and IL-1beta/H2O2 co-stimulation caused four and two fold induction of NF-kappaB activity in non-CF and CF cells, respectively. IL-8 levels in unstimulated CF cells were significantly higher than in non-CF cells (P=0.0025). Upon incubation with P. aeruginosa and IL-1beta/H2O2, non-CF cells produced 6.3 times more IL-8 than unstimulated cells, whereas IL-8 secretion increased only of 1.4 times in CF cells.
CONCLUSIONS: CF respiratory epithelial cells exhibit a basal dysregulated production of IL-8 that partially correlates to enhanced NF-kappaB activity. Our data corroborate the hypothesis of a basal exaggerated inflammatory response in the CF respiratory epithelium.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16481223     DOI: 10.1016/j.jcf.2005.12.003

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  25 in total

Review 1.  Overcoming reduced glucocorticoid sensitivity in airway disease: molecular mechanisms and therapeutic approaches.

Authors:  John A Marwick; Ian M Adcock; Kian Fan Chung
Journal:  Drugs       Date:  2010-05-28       Impact factor: 9.546

2.  Azithromycin selectively reduces tumor necrosis factor alpha levels in cystic fibrosis airway epithelial cells.

Authors:  Cristina Cigana; Baroukh Maurice Assael; Paola Melotti
Journal:  Antimicrob Agents Chemother       Date:  2007-01-08       Impact factor: 5.191

3.  Does the F508-CFTR mutation induce a proinflammatory response in human airway epithelial cells?

Authors:  Thomas H Hampton; Alicia E Ballok; Jennifer M Bomberger; Melanie R Rutkowski; Roxanna Barnaby; Bonita Coutermarsh; José R Conejo-Garcia; George A O'Toole; Bruce A Stanton
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-07-20       Impact factor: 5.464

Review 4.  Mechanisms of action and clinical application of macrolides as immunomodulatory medications.

Authors:  Soichiro Kanoh; Bruce K Rubin
Journal:  Clin Microbiol Rev       Date:  2010-07       Impact factor: 26.132

5.  Myeloperoxidase-dependent oxidative metabolism of nitric oxide in the cystic fibrosis airway.

Authors:  Anna L P Chapman; Brian M Morrissey; Vihas T Vasu; Maya M Juarez; Jessica S Houghton; Chin-Shang Li; Carroll E Cross; Jason P Eiserich
Journal:  J Cyst Fibros       Date:  2010-01-15       Impact factor: 5.482

6.  Expression of wild-type CFTR suppresses NF-kappaB-driven inflammatory signalling.

Authors:  Mairi J Hunter; Kate J Treharne; Alexandra K Winter; Diane M Cassidy; Stephen Land; Anil Mehta
Journal:  PLoS One       Date:  2010-07-14       Impact factor: 3.240

7.  Newborn Cystic Fibrosis Pigs Have a Blunted Early Response to an Inflammatory Stimulus.

Authors:  Jennifer A Bartlett; Shyam Ramachandran; Christine L Wohlford-Lenane; Carrie K Barker; Alejandro A Pezzulo; Joseph Zabner; Michael J Welsh; David K Meyerholz; David A Stoltz; Paul B McCray
Journal:  Am J Respir Crit Care Med       Date:  2016-10-01       Impact factor: 21.405

Review 8.  Dysregulated Chemokine Signaling in Cystic Fibrosis Lung Disease: A Potential Therapeutic Target.

Authors:  Xiaoqing Guan; Yuning Hou; Fei Sun; Zhe Yang; Chunying Li
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

9.  TLR-4-mediated innate immunity is reduced in cystic fibrosis airway cells.

Authors:  Gerrit John; Ali O Yildirim; Bruce K Rubin; Dieter C Gruenert; Markus O Henke
Journal:  Am J Respir Cell Mol Biol       Date:  2009-06-05       Impact factor: 6.914

10.  Corr4A and VRT325 do not reduce the inflammatory response to P. aeruginosa in human cystic fibrosis airway epithelial cells.

Authors:  Laleh Talebian; Bonita Coutermarsh; Jacqueline Y Channon; Bruce A Stanton
Journal:  Cell Physiol Biochem       Date:  2009-02-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.